Dihydrofolate reductase inhibitors

US8835445B2 · kind B2 · utility

Assignee

• Trius Therapeutics, Inc. · US

Inventors

• Zhiyong Chen · San Diego, US
• Christopher J. Creighton · San Diego, US
• Mark Cunningham · Kennett Square, US
• John Finn · Mercerville, US
• Mark Hilgers · San Diego, US
• Michael E. Jung · Los Angeles, US
• Lucy Aguirre Kohnen · Cambridge, US
• Thanh To Lam · San Diego, US
• Xiaoming Li · Irvine, US
• Mark Stidham · San Diego, US
• Les Tari · San Diego, US
• Michael Trzoss · San Diego, US
• Junhu Zhang · San Diego, US

Key dates

• Filing date: Jun 2, 2011
• Grant date: Sep 16, 2014
• Expiry date: Aug 14, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds of Formula I:or a pharmaceutically acceptable salt thereof, wherein R5, R6 and Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of Formula I.